Cactus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-12-2024
- Paid Up Capital ₹ 1.00 M
as on 16-12-2024
- Company Age 10 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.15 M
as on 16-12-2024
- Revenue 23.28%
(FY 2022)
- Profit 19.48%
(FY 2022)
- Ebitda 86.10%
(FY 2022)
- Net Worth 43.37%
(FY 2022)
- Total Assets 36.05%
(FY 2022)
About Cactus Pharmaceuticals
The Corporate was formerly known as Cactus Phermaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.15 M.
Raihana Khatun and Mohammad Muntazir serve as directors at the Company.
- CIN/LLPIN
U24100UP2014PTC062147
- Company No.
062147
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jan 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- LocationGreater Noida, Uttar Pradesh
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Cactus Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raihana Khatun  | Director | 22-Jan-2014 | Current |
| Mohammad Muntazir | Director | 22-Jan-2014 | Current |
Financial Performance of Cactus Pharmaceuticals.
Cactus Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 23.28% increase. The company also saw a substantial improvement in profitability, with a 19.48% increase in profit. The company's net worth Soared by an impressive increase of 43.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cactus Pharmaceuticals?
In 2021, Cactus Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sufia Memorial Hospital Private LimitedActive 15 years 3 monthsRaihana Khatun and Mohammad Muntazir are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 05 Oct 2021 | ₹1.15 M | Open |
How Many Employees Work at Cactus Pharmaceuticals?
Unlock and access historical data on people associated with Cactus Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cactus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cactus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
